NCT01361295

Brief Summary

Radiofrequency catheter ablation of atrial fibrillation (AF) induces a procoagulant state, which leads to an acute risk for symptomatic cerebral embolism (CE) of approximately 1%. The induction of a procoagulant state has been studied in pulmonary vein isolation (PVI) with a non-cooled tip catheter. The induction of a procoagulant state using a cooled-tip catheter has not been studied yet. Due to the avoidance of high endocardial temperatures, it can be expected that these procedures induce a lower level of procoagulation. Recent studies showed an 11% incidence of CE on diffusion weighted (DW) MRI in patients undergoing cooled-tip catheter ablation of AF. In this study there will be used to different catheters, the cooled-tip catheter and the PVAC Gold catheter. Since the PVAC Gold catheter is equipped with non-cooled electrodes, the risk of endothelial scarring, local thrombosis and CE may be increased. The goal of this study is to determine the effect of two different ablation catheters on the induction of a procoagulant state and the incidence of CE on DW-MRI in patients with AF undergoing PVI. Our hypothesis is that patients with AF undergoing PVI using the PVAC gold catheter will show a higher rise in procoagulation and a higher incidence of CE on DW-MRI than patients with AF undergoing PVI with the cooled-tip catheter.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for not_applicable atrial-fibrillation

Timeline
Completed

Started Mar 2015

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 26, 2011

Completed
3.8 years until next milestone

Study Start

First participant enrolled

March 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

September 2, 2020

Status Verified

September 1, 2020

Enrollment Period

2 years

First QC Date

May 20, 2011

Last Update Submit

September 1, 2020

Conditions

Keywords

Atrial fibrillationcerebral embolismcatheter ablation

Outcome Measures

Primary Outcomes (1)

  • Cerebral embolism

    Cerebral embolism will be documented with diffusion weighted MRI of the brain before and after ablation.

    Between 24 hours before the ablation and 24 hours after the ablation

Secondary Outcomes (2)

  • Neuropsychological functioning

    Between a week before the ablation until 3 months after the ablation

  • Rise in procoagulation

    Between 24 hours before the ablation and 24 hours after the ablation

Study Arms (2)

PVI with PVAC gold

ACTIVE COMPARATOR

Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.

Procedure: PVI with Cooled-RF

PVI with Cooled-RF

ACTIVE COMPARATOR

Patient for pulmonal vein isolation using the Cooled-RF catheter.

Procedure: PVI with PVAC gold

Interventions

Pulmonary vein isolation using the Medtronic PVAC gold catheter

Also known as: Medtronic AF solutions
PVI with Cooled-RF

Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter

Also known as: CARTO3 system
PVI with PVAC gold

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • suffering from drug-refractory paroxysmal atrial fibrillation
  • scheduled for first ablation procedure

You may not qualify if:

  • contra-indications for DW-MRI
  • previous AF-ablation
  • minors
  • any patient unable to undergo neuropsychological testing due to mental retardation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Leiden University Medical Center

Leiden, South Holland, Netherlands

Location

Related Publications (4)

  • Sauren LD, VAN Belle Y, DE Roy L, Pison L, LA Meir M, VAN DER Veen FH, Crijns HJ, Jordaens L, Mess WH, Maessen JG. Transcranial measurement of cerebral microembolic signals during endocardial pulmonary vein isolation: comparison of three different ablation techniques. J Cardiovasc Electrophysiol. 2009 Oct;20(10):1102-7. doi: 10.1111/j.1540-8167.2009.01509.x. Epub 2009 Jun 22.

    PMID: 19549035BACKGROUND
  • Schrickel JW, Lickfett L, Lewalter T, Mittman-Braun E, Selbach S, Strach K, Nahle CP, Schwab JO, Linhart M, Andrie R, Nickenig G, Sommer T. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace. 2010 Jan;12(1):52-7. doi: 10.1093/europace/eup350.

    PMID: 19933517BACKGROUND
  • Bulava A, Slavik L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcova V, Indrak K. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol. 2004 Jun;10(3):271-9. doi: 10.1023/B:JICE.0000026924.96281.be.

    PMID: 15133367BACKGROUND
  • Kece F, Bruggemans EF, de Riva M, Alizadeh Dehnavi R, Wijnmaalen AP, Meulman TJ, Brugman JA, Rooijmans AM, van Buchem MA, Middelkoop HA, Eikenboom J, Schalij MJ, Zeppenfeld K, Trines SA. Incidence and Clinical Significance of Cerebral Embolism During Atrial Fibrillation Ablation With Duty-Cycled Phased-Radiofrequency Versus Cooled-Radiofrequency: A Randomized Controlled Trial. JACC Clin Electrophysiol. 2019 Mar;5(3):318-326. doi: 10.1016/j.jacep.2018.11.008. Epub 2018 Dec 26.

MeSH Terms

Conditions

Atrial FibrillationIntracranial Embolism

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsIntracranial Embolism and ThrombosisCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesThromboembolismEmbolism and Thrombosis

Study Officials

  • Serge A. Trines, MD, PhD

    Cardiology, LUMC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Senior cardiologist

Study Record Dates

First Submitted

May 20, 2011

First Posted

May 26, 2011

Study Start

March 1, 2015

Primary Completion

March 1, 2017

Study Completion

December 1, 2017

Last Updated

September 2, 2020

Record last verified: 2020-09

Locations